Funding: NIDDK
Investigator: Reese, P; Schaubel, D; Goldberg, D
The CRCU serves as the Data Coordinating Center for the THINKER-NEXT trial. The THINKER-NEXT trial, led by Peter Reese, MD and Douglas Schaubel PhD at The Perelman School of Medicine and David Goldberg, MD at the University of Miami in Florida, is a single arm open-label NIDDK-funded clinical trial. The main objective of the study is to estimate the hepatitis C virus (HCV) cure rate after transplantation, using kidneys from HCV-infected deceased donors for HCV-negative recipients, followed by treatment with direct acting antivirals